Cyclooxygenase-2 inhibition prevents renal toxicity but not hypertension during sunitinib treatment

被引:0
|
作者
van Dorst, Daan C. H. [1 ,2 ,6 ]
Colafella, Katrina M. Mirabito [3 ,4 ]
van Veghel, Richard [1 ]
Garrelds, Ingrid M. [1 ]
de Vries, Rene [1 ]
Mathijssen, Ron H. J. [2 ]
Danser, A. H. Jan [1 ]
Versmissen, Jorie [1 ,5 ]
机构
[1] Erasmus MC Univ Med Ctr, Dept Internal Med, Div Vasc Med & Pharmacol, Rotterdam, Netherlands
[2] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[3] Monash Univ, Biomed Discovery Inst, Cardiovasc Dis Program, Melbourne, Australia
[4] Monash Univ, Dept Physiol, Melbourne, Australia
[5] Erasmus MC Univ Med Ctr, Dept Hosp Pharm, Rotterdam, Netherlands
[6] Dept Internal Med, Div Pharmacol & Vasc Med, room EE-1424 Erasmus MC Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands
关键词
Cardio-oncology; Angiogenesis inhibitors; Hypertension; Renal toxicity; Cyclooxygenase-2; Prostanoids; BLOOD-PRESSURE; PROSTACYCLIN SYNTHESIS; ARACHIDONIC-ACID; CELECOXIB; COX-2; ACTIVATION; ILOPROST; MODEL;
D O I
10.1016/j.ejphar.2023.176199
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Anticancer angiogenesis inhibitors cause hypertension and renal injury. Previously we observed in rats that high-dose aspirin (capable of blocking cyclooxygenase (COX)-1 and-2) was superior to low-dose aspirin (blocking COX-1 only) to prevent these side-effects during treatment with the angiogenesis inhibitor sunitinib, suggesting a role for COX-2. High-dose aspirin additionally prevented the rise in COX-derived prostacyclin (PGI(2)). Therefore, we studied the preventive effects of selective COX-2 inhibition and the hypothesized contributing role of PGI(2) during angiogenesis inhibition.Methods: Male WKY rats received vehicle, sunitinib ((SU), 14 mg/kg/day) alone or combined with COX-2 inhibition (celecoxib, 10 mg/kg/day) or a PGI(2) analogue (iloprost, 100 mu g/kg/day) for 8 days (n = 8-9 per group). Mean arterial pressure (MAP) was measured via radiotelemetry, biochemical measurements were performed via ELISA and vascular function was assessed via wire myography.Results: SU increased MAP (17 +/- 1mmHg versus 3 +/- 1mmHg after vehicle on day 4, P < 0.002), which could not be significantly blunted by celecoxib (+12 +/- 3mmHg on day 4, P = 0.247), but was temporarily attenuated by iloprost (treatment days 1 + 2 only). Urinary PGI(2) (996 +/- 112 versus 51 +/- 11ng/24h after vehicle, P < 0.001), but not circulating PGI(2) increased during SU, which remained unaffected by celecoxib and iloprost. Celecoxib reduced sunitinib-induced albuminuria (0.36 +/- 0.05 versus 0.58 +/- 0.05mg/24h after SU, P = 0.005). Wire myography demonstrated increased vasoconstriction to endothelin-1 after SU (Emax P = 0.005 versus vehicle), which remained unaffected by celecoxib or iloprost.Conclusion: Selective COX-2 inhibition ameliorates albuminuria during angiogenesis inhibition with sunitinib, which most likely acts independently of PGI(2). To combat angiogenesis inhibitor-induced hypertension, dual rather than selective COX-1/2 blockade seems preferential.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Cyclooxygenase-2 inhibition improves antioxidative defense during experimental hypercholesterolemia
    Ahmed, Sagheer
    Gul, Saima
    Gul, Humera
    Zia-Ul-Haq, Muhammad
    Ercisli, Sezai
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2014, 14 (02) : 63 - 69
  • [42] Renal medullary cyclooxygenase-2 and (pro)renin receptor expression during angiotensin II-dependent hypertension
    Gonzalez, Alexis A.
    Green, Torrance
    Luffman, Christina
    Bourgeois, Camille R. T.
    Navar, L. Gabriel
    Prieto, Minolfa C.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2014, 307 (08) : F962 - F970
  • [43] Renal hemodynamic responses to cyclooxygenase-2 inhibition in rats during acute and chronic angiotensin-converting enzyme inhibition.
    Green, T
    Rodriguez, J
    Navar, LG
    JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (01) : S312 - S313
  • [44] Inhibition of cyclooxygenase-2 prevents intra-abdominal adhesions by decreasing activity of peritoneal fibroblasts
    Wei, Guangbing
    Chen, Xin
    Wang, Guanghui
    Jia, Pengbo
    Xu, Qinhong
    Ping, Gaofeng
    Wang, Kang
    Li, Xuqi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3083 - 3098
  • [45] Cyclooxygenase-2 inhibition prevents stress induced amygdala activation and anxiety-like behavior
    Morgan, Amanda
    Gaulden, Andrew
    Altemus, Megan
    Williford, Kellie
    Centanni, Samuel
    Winder, Danny
    Patel, Sachin
    BRAIN BEHAVIOR AND IMMUNITY, 2020, 89 : 513 - 517
  • [46] Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats
    Peter, D.
    Goeggel, R.
    Colbatzky, F.
    Nickolaus, P.
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 162 (02) : 415 - 427
  • [47] Inhibition of cyclooxygenase-2 prevents myocardial dysfunction and improves cardiomyocyte survival in ischemic heart failure
    Saito, T
    Rodger, IW
    Hu, F
    Huynh, T
    Giald, A
    CIRCULATION, 2000, 102 (18) : 200 - 200
  • [48] Celecoxib, a specific cyclooxygenase-2 inhibitor prevents appearance of preneoplasic lesions during hepatocarcinogenesis
    Márquez-Rosado, L
    Villa-Treviño, S
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 113 - 113
  • [49] Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension
    Cheng, HF
    Wang, CJ
    Moeckel, GW
    Zhang, MZ
    McKanna, JA
    Harris, RC
    KIDNEY INTERNATIONAL, 2002, 62 (03) : 929 - 939
  • [50] INHIBITION OF CYCLOOXYGENASE-2 IMPACTS CHONDROCYTE HYPERTROPHY
    Caron, M. J.
    Emans, P. J.
    Janssen, M. P.
    Sanen, K.
    Coolsen, M. M.
    Voss, L.
    Surtel, D. A.
    Cremers, A.
    Voncken, J. -W.
    Welting, T. J.
    van Rhijn, L. W.
    OSTEOARTHRITIS AND CARTILAGE, 2012, 20 : S139 - S139